Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
1
Rheumatology & Immuno-Mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS-UVIGO, 36201 Vigo, Spain
2
Rheumatology Department, University Hospital Complex of Vigo, 36201 Vigo, Spain
*
Author to whom correspondence should be addressed.
†
These authors equally contributed to this work.
Int. J. Mol. Sci. 2020, 21(19), 7100; https://doi.org/10.3390/ijms21197100
Received: 31 August 2020 / Revised: 17 September 2020 / Accepted: 24 September 2020 / Published: 26 September 2020
(This article belongs to the Special Issue Pro-inflammatory and Anti-inflammatory Cytokines in Autoimmune Diseases)
Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option.
View Full-Text
Keywords:
Interleukin-17; systemic rheumatic diseases; T helper 17 cells; Sjögren’s syndrome; systemic lupus erythematosus; systemic sclerosis; therapeutic target
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Rafael-Vidal, C.; Pérez, N.; Altabás, I.; Garcia, S.; Pego-Reigosa, J.M. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. Int. J. Mol. Sci. 2020, 21, 7100. https://doi.org/10.3390/ijms21197100
AMA Style
Rafael-Vidal C, Pérez N, Altabás I, Garcia S, Pego-Reigosa JM. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. International Journal of Molecular Sciences. 2020; 21(19):7100. https://doi.org/10.3390/ijms21197100
Chicago/Turabian StyleRafael-Vidal, Carlos; Pérez, Nair; Altabás, Irene; Garcia, Samuel; Pego-Reigosa, Jose M. 2020. "Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases" Int. J. Mol. Sci. 21, no. 19: 7100. https://doi.org/10.3390/ijms21197100
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit